Organisation paid for research Program year 2025 Source: CMS Open Payments

Mgcendo LLC

Neither a doctor nor a teaching hospital

Research payments

$3,321,858

24 payments

Through program year 2025, Mgcendo LLC is reported as receiving $3,321,858 in research payments, across 24 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$668,273	6
2024	Research	$1,051,217	8
2023	Research	$1,099,749	7
2022	Research	$502,619	3

Breakdown

Who paid Research payments · program years 2022–2025

Eli Lilly Export S.A. Puerto Rico Branch $3,308,420 16 payments
Eli Lilly and Company $13,438 8 payments

Studies the money was for Research payments · program years 2022–2025

A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $603,784 4 payments
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of Ly3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (Qwint-3) $517,359 2 payments
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $464,838 4 payments
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $387,649 4 payments
A Phase 3 Multicenter Randomized Parallel-Design Open-Label Trial to Evaluate the Efficacy and Safety of Ly3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (Qwint-3) $379,936 1 payment
A Phase 3 Multicenter Randomized Parallel-Design Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $371,493 1 payment
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $218,009 2 payments
A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $216,814 2 payments
A Phase 3 Randomized Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $105,415 2 payments
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $30,471 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.